Community Takeaways From ASCO GU 2026
Key Points
-
Perioperative enfortumab vedotin plus pembrolizumab improved outcomes compared with standard neoadjuvant chemotherapy in the phase 3 KEYNOTE-B15/EV-304 trial.
-
Data suggest that circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) may be valuable tools to guide treatment decisions in muscle-invasive bladder cancer (MIBC).
-
Intensifying hormone therapy with radioligands or PARP inhibitors showed positive improvements in outcomes across prostate cancer trials.
ASCO GU 2026 Takeaways for Community GU Oncologists
At an event coinciding with the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026), Regina Barragán-Carrillo, MD, of Instituto Nacional de Cancerología, and Raji Shameem, MD, of Orlando Health, discussed key takeaways for community medical oncologists treating patients with genitourinary (GU) cancers.
ASCO GU 2026 featured transformative data for MIBC, particularly the KEYNOTE-B15/EV-304 data on perioperative enfortumab vedotin plus pembrolizumab in cisplatin–eligible patients with MIBC. The data support community oncologists implementing this regimen once they are ready to manage the unique side effects, such as rash and neuropathy. Other presentations at ASCO GU 2026 continue to explore the role of ctDNA and utDNA in MIBC. However, more trials are ultimately needed before it can be used to guide treatment decisions, said Dr. Shameem.
The doctors also highlighted key data from prostate cancer trials, including the overall survival benefit reported with the addition of radium-223 to enzalutamide in the EORTC-1333-GUCG/PEACE III trial. In addition, trials such as BRCAAway and EvoPAR-Prostate02 showed the potential benefit of combining PARP inhibitors with androgen receptor pathway inhibitors in castration–sensitive and castration–resistant prostate cancer with BRCA mutations. Taken together, the studies emphasize the importance of next-generation sequencing (NGS) to identify relevant mutations and guide frontline treatment decisions in patients with prostate cancer.